Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

NCT04175262 · clinicaltrials.gov ↗
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer

Collaborators